Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 9 results.
User Information
Export Records
  1. 1.   Antitumor Activity of a Novel Oncrasin Analogue Is Mediated by JNK Activation and STAT3 Inhibition
  2. Guo, W.; Wu, S. H.; Wang, L.; Wei, X. L.; Liu, X. Y.; Wang, J.; Lu, Z. M.; Hollingshead, M.; Fang, B. L.
  3. Plos One. 2011, Dec; 6(12):
  1. 2.   The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo
  2. Lucas, D. M.; Edwards, R. B.; Lozanski, G.; West, D. A.; Shin, J. D.; Vargo, M. A.; Davis, M. E.; Rozewski, D. M.; Johnson, A. J.; Su, B. N.; Goettl, V. M.; Heerema, N. A.; Lin, T. S.; Lehman, A.; Zhang, X. L.; Jarjoura, D.; Newman, D. J.; Byrd, J. C.
  3. Blood. 2009 113(19): 4656-4666.
  1. 3.   Induction of apoptosis by flavopiridol in human neuroblastoma cells is enhanced under hypoxia and associated with N-myc proto-oncogene down-regulation
  2. Puppo, M.; Pastorino, S.; Melillo, G.; Pezzolo, A.; Varesio, L.; Bosco, M. C.
  3. Clinical Cancer Research. 2004, DEC 15; 10(24): 8704-8719.
  1. 4.   Clinical pharmacology of flavopiridol following a 72-hour continuous infusion
  2. Rudek, M. A.; Bauer, K. S.; Lush, R. M.; Stinson, S. F.; Senderowicz, A. M.; Headlee, D. J.; Arbuck, S. G.; Cox, M. C.; Murgo, A. J.; Sausville, E. A.; Figg, W. D.
  3. Annals of Pharmacotherapy. 2003 37(10): 1369-1374.
  1. 5.   Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms
  2. Tan, A. R.; Headlee, D.; Messmann, R.; Sausville, E. A.; Arbuck, S. G.; Murgo, A. J.; Melillo, G.; Zhai, S. P.; Figg, W. D.; Swain, S. M.; Senderowicz, A. M.
  3. Journal of Clinical Oncology. 2002 20(19): 4074-4082.
  1. 6.   Flavopiridol inhibits vascular endothelial growth factor production induced by hypoxia or picolinic acid in human neuroblastoma
  2. Rapella, A.; Negrioli, A.; Melillo, G.; Pastorino, S.; Varesio, L.; Bosco, M. C.
  3. International Journal of Cancer. 2002 99(5): 658-664.
  1. 7.   Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition
  2. Gussio, R.; Zaharevitz, D. W.; McGrath, C. F.; Pattabiraman, N.; Kellogg, G. E.; Schultz, C.; Link, A.; Kunick, C.; Leost, M.; Meijer, L.; Sausville, E. A.
  3. Anti-Cancer Drug Design. 2000 15(1): 53-66.
  1. 8.   The hollow fiber assay: Continued characterization with novel approaches
  2. Hall, L. M.; Krauthauser, C. M.; Wexler, R. S.; Hollingshead, M. G.; Slee, A. M.; Kerr, J. S.
  3. Anticancer Research. 2000 20(2A): 903-911.
  1. 9.   Determination of Flavopiridol (L86 8275 Nsc 649890) in Human Plasma By Reversed-Phase Liquid Chromatography With Electrochemical Detection
  2. Stinson, S. F.; Hill, K.; Siford, T. J.; Phillips, L. R.; Daw, T. W.
  3. Cancer Chemotherapy and Pharmacology. 1998 42(4): 261-265.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel